نتایج جستجو برای: atenolol

تعداد نتایج: 2057  

Journal: :The Journal of pharmacology and experimental therapeutics 2016
Jia Yin Haichuan Duan Joanne Wang

Renal transporter-mediated drug-drug interactions (DDIs) are of significant clinical concern, as they can adversely impact drug disposition, efficacy, and toxicity. Emerging evidence suggests that human renal organic cation transporter 2 (hOCT2) and multidrug and toxin extrusion proteins 1 and 2-K (hMATE1/2-K) exhibit substrate-dependent inhibition, but their impact on renal drug secretion and ...

Journal: :Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1998
A J Branten L B Hilbrands H W van Hamersvelt R A Koene F T Huysmans

BACKGROUND Hypertension and nephrotoxicity are well-known side-effects of cyclosporine A (CsA). CsA-induced vasoconstriction of the afferent glomerular arteriole probably plays a role in at least the nephrotoxicity. Frequently renal transplant recipients on CsA have to be treated with antihypertensive drugs and for this purpose also beta-blockers are used. Tertatolol is a new beta-blocker with ...

Journal: :Journal of hypertension 2011
David J Collier Neil R Poulter Björn Dahlöf Peter S Sever Hans Wedel Jan Buch Mark J Caulfield

OBJECTIVES Older patients experience higher rates of cardiovascular disease than younger patients, but studies have suggested that relative risk reductions due to antihypertensive therapy are lower in older than younger patients. The Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) allowed an evaluation of the efficacy and safety of an amlodipine versus an aten...

2004
Niels H. Buus Morten Bøttcher Claus G. Jørgensen Kent L. Christensen Kristian Thygesen Torsten T. Nielsen Michael J. Mulvany

Hypertension is associated with reduced coronary vasodilatory capacity, possibly caused by structural changes in the coronary resistance vessels. Because vasodilatory treatment may correct abnormal structure better than nonvasodilating treatment, we compared whether long-term angiotensin-converting enzyme (ACE) inhibition has a greater effect on coronary reserve and cardiovascular structure tha...

2005
Astrid E. Fletcher Christopher J. Bulpitt Dagmar M. Chase William C.J. Collins Curt D. Furberg Timothy K. Goggin Andrew J. Hewett

A multicenter, randomized double-blind study of 6 months' duration was performed in 540 patients (average age 54 years, 57% male) with mild-to-moderate essential hypertension to determine the relative effects on quality of life of cilazapril, atenolol, and nifedipine retard. Quality of life was assessed by using both a self-administered and an interviewer-administered questionnaire; the assessm...

Journal: :Journal of the American College of Cardiology 2005
Kristian Wachtell Mika Lehto Eva Gerdts Michael H Olsen Björn Hornestam Björn Dahlöf Hans Ibsen Stevo Julius Sverre E Kjeldsen Lars H Lindholm Markku S Nieminen Richard B Devereux

OBJECTIVES This study was designed to evaluate whether different antihypertensive treatment regimens with similar blood pressure reduction have different effects on new-onset atrial fibrillation (AF). BACKGROUND It is unknown whether angiotensin II receptor blockade is better than beta-blockade in preventing new-onset AF. METHODS In the Losartan Intervention For Endpoint reduction in hypert...

Journal: :American journal of hypertension 2012
Anders M Greve Michael H Olsen Jonathan N Bella Mai T Lønnebakken Eva Gerdts Peter M Okin Vittorio Palmieri Kurt Boman Markku S Nieminen Per Omvik Björn Dahlöf Richard B Devereux Kristian Wachtell

BACKGROUND Pharmaceutical differences in central hemodynamics might influence cardiac response to antihypertensive treatment despite similar lowering of brachial blood pressure (BP). METHODS Data from all patients with at least two echocardiographic examinations in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) echocardiographic substudy (n = 801); high-risk patients ...

Journal: :Hypertension 2004
Niels H Buus Morten Bøttcher Claus G Jørgensen Kent L Christensen Kristian Thygesen Torsten T Nielsen Michael J Mulvany

Hypertension is associated with reduced coronary vasodilatory capacity, possibly caused by structural changes in the coronary resistance vessels. Because vasodilatory treatment may correct abnormal structure better than nonvasodilating treatment, we compared whether long-term angiotensin-converting enzyme (ACE) inhibition has a greater effect on coronary reserve and cardiovascular structure tha...

Journal: :Hypertension 2005
Frej Fyhrquist Björn Dahlöf Richard B Devereux Sverre E Kjeldsen Stevo Julius Gareth Beevers Ulf de Faire Hans Ibsen Krister Kristianson Ole Lederballe-Pedersen Lars H Lindholm Markku S Nieminen Per Omvik Suzanne Oparil Darcy A Hille Paulette A Lyle Jonathan M Edelman Steven M Snapinn Hans Wedel

In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy. The objective of this post hoc analysis was to determine the influence of pulse pressure on outcome. Patients were divid...

Journal: :PharmacoEconomics 2006
Aslam H Anis Huiying Sun Sonia Singh John Woolcott Bohdan Nosyk Marc Brisson

INTRODUCTION The LIFE (Losartan Intervention For Endpoint reduction in hypertension) study demonstrated a 13% relative risk reduction in the primary composite endpoint (myocardial infarction, stroke or death) for patients with hypertension and electrocardiographically diagnosed left ventricular hypertrophy (LVH) treated with losartan compared with atenolol. Losartan recipients also had a 25% re...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید